There are currently 85 clinical trials in Wilmington, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including PMG Research of Wilmington, LLC, GSK Investigational Site, PMG Research of Wilmington and New Hanover Regional Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Recruiting
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Accellacare - Wilmington, Wilmington, North Carolina
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Recruiting
The primary objective of the study is to assess the efficacy of high dose and low dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). Secondary Objectives: To evaluate the efficacy of Fp/ABS compared to ABS and the effect on systemic corticosteroid (SCS) exposure To evaluate the safety and tolerability of Fp/A BS The duration for each particip... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
04/17/2025
Locations: Teva Investigational Site 15631, Wilmington, North Carolina
Conditions: Asthma
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
04/17/2025
Locations: Accellacare - Wilmington - 1917 Tradd Court, Wilmington, North Carolina
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Recruiting
Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at ti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Accellacare - Wilmington, Wilmington, North Carolina
Conditions: OSA, Overweight or Obesity
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
Recruiting
This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/16/2025
Locations: Accellacare of Wilmington, Wilmington, North Carolina
Conditions: Non-cystic Fibrosis Bronchiectasis
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
Recruiting
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Gender:
ALL
Ages:
Between 10 years and 65 years
Trial Updated:
04/16/2025
Locations: Eastern Nephrology Associates - Wilmington Office, Wilmington, North Carolina
Conditions: Proteinuric Kidney Disease
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Recruiting
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/16/2025
Locations: Accellacare - Wilmington - 1917 Tradd Court, Wilmington, North Carolina
Conditions: Type 2 Diabetes, Obesity
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Recruiting
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Novant Health New Hanover Regional Medical Center, Wilmington, North Carolina
Conditions: Endometrial Serous Adenocarcinoma, Uterine Corpus Carcinosarcoma, Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Undifferentiated Carcinoma
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
Recruiting
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/15/2025
Locations: Accellacare Wilmington, Wilmington, North Carolina +1 locations
Conditions: Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/15/2025
Locations: Accellacare US Inc. of Wilmington, Wilmington, North Carolina
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/15/2025
Locations: Accellacare US Inc. of Wilmington, Wilmington, North Carolina
Conditions: Progressive Pulmonary Fibrosis
A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
Recruiting
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/14/2025
Locations: Accellacare of Wilmington, LLC, Wilmington, North Carolina
Conditions: Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)